 |
2004
OMIG, Abstract 4
OMIG
Main Page | 2004
Abstracts | < Previous
| Next >
Passive
Immunization Therapy for Experimental Staphylococcal Keratitis
AR Caballero, JT Bush, JJ Dajcs, ME Marquart, BA Thibodeaux, RJ
O'Callaghan. LSU Health Sciences Center, Department of Microbiology,
New Orleans, Louisiana
Purpose:
To determine the value of antibody to alpha-toxin as a therapy for
Staphylococcus aureus keratitis.
Methods: High titered rabbit antibody (ELISA titer
= >20,000) to alpha-toxin was injected into rabbits subconjunctivally
at 6 and 12 hrs postinfection (PI) or intravenously at either 24
hrs before infection or 6 and 12 hrs PI. Rabbit corneas were injected
intrastromally with 100 CFU of S. aureus. Corneal erosion measurements
and slit lamp scoring (SLE) were performed at 15, 20, and 25 hrs
PI, and the log number colony forming units (CFU) per cornea were
determined at 25 hrs PI.
Results: Subconjunctival injection of antibody
at 6 and 12 hrs PI caused a significant reduction in the SLE score
at 25 hrs PI (P = 0.0051); corneal erosions were significantly reduced
at 25 hrs PI (P =0.0038). Injection of antibody intravenously 24
hrs before infection caused significant reductions in the SLE scores
at 20 and 25 hrs PI (P = 0.008 and P< 0.0001, respectively);
corneal erosions were significantly reduced at 15, 20, and 25 hrs
PI (P = 0.029, P = 0.0012, P < 0.0001, respectively). Intravenous
injection of antibody at 6 hrs PI caused a significant reduction
in the SLE score at 15, 20, and 25 hrs PI (P = 0.0056, P = 0.0008,
and P = 0.0026, respectively); corneal erosions were also significantly
reduced at 25 hrs PI (P = 0.016). Injection of antibody before or
during the infection by the intravenous or subconjunctival route
did not significantly reduce the log CFU per cornea (P >
0.149) and both treated and untreated corneas contained approximately
10 million CFU of S.aureus.
Conclusions: Antibody to alpha-toxin administered
by either the intravenous or subconjunctival routes protected the
corneal epithelium and reduced overall pathology during experimental
S. aureus keratitis
Disclosure
code: N
OMIG
Main Page | 2004
Abstracts | < Previous
| Next >
|
|
|
